36 completed, 13 recruiting, 12 terminated, 9 unknown. 44 Phase 2, 28 Phase 3, 10 Phase 1, 6 Phase 4, 4 Not applicable.
Follow Megestrol Acetate: new trials by email Literature Review of Megestrol Acetate trials Research Report on Megestrol Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer medroxyprogesterone acetate tablets OR megestrol acetate, Cisplatin, Carboplatin + Paclitaxel - Endometrial Cancer, Uterine Neoplasms | Phase 3 | Recruiting | University College, London | 600 | 2026-06-29 | 2026-09-21 |
| Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial Biopsy Procedure, Curettage Procedure, Hysterectomy - Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia | Phase 2 | Recruiting | New Mexico Cancer Research Alliance | 140 | 2026-06-15 | 2026-07-02 |
| Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer Megestrol Acetate + Trastuzumab Deruxtecan, Placebo + Trastuzumab Deruxtecan - Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 132 | 2026-06-08 | 2026-08-14 |
| Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification PD1 antibody, Medroxyprogesterone Acetate 500 MG, Megestrol Acetate 160 MG - Endometrial Cancer, Fertility | Phase 2 / Phase 3 | Recruiting | Fudan University | 260 | 2026-01-25 | 2026-03-13 |
| A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients NEPA, Dexamethasone, Megestrol Acetate - Breast Cancer Patients Treated With T-DXd | Phase 4 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2025-12-15 | 2025-11-28 |
| Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC Megestrol Acetate - Neoadjuvant Chemotherapy, Weight Loss | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 60 | 2025-11-11 | 2025-12-12 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA) - Endometrial Cancer, Endometrioid Carcinoma | Not applicable | Recruiting | Peking University People's Hospital | 10 | 2024-09-02 | 2026-08-10 |
| Nutrition Impact on Immunotherapy of Cancer Megestrol Acetate and olanzapine, Starch powder 50 mg - Nutrition Disorders, Immunotherapy | Phase 3 | Recruiting | Qingdao Central Hospital | 300 | 2024-06-01 | 2024-07-15 |
| Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Relugolix, Relugolix placebo - Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 120 | 2024-01-15 | 2026-02-02 |
| Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women Megestrol Acetate 40 MG - Endometrial Cancer Stage I, Endometrial Hyperplasia | Not applicable | Recruiting | Women's Hospital School Of Medicine Zhejiang University | 75 | 2023-12-01 | 2024-05-16 |
| Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia Megestrol Acetate, Levonorgestrel Drug Implant - Endometrial Hyperplasia | Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2023-06-30 | 2023-07-05 | |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Biospecimen Collection, Computed Tomography, Ipatasertib - FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2023-03-31 | 2026-10-01 |
| Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer Megestrol Acetate - Endometrial Cancer | Phase 1 | Terminated | Sunnybrook Health Sciences Centre | 5 | 2022-07-05 | 2023-11-03 |
| Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg - Atypical Endometrial Hyperplasia, Fertility Issues | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 172 | 2022-06-13 | 2026-06-04 |
| Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG, Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo - Adrenocortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 80 | 2022-06-08 | 2024-08-01 |
| Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients. Mirtazapine, Megestrol Acetate - Anorexia | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 80 | 2022-06-01 | 2022-05-18 |
| Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet - Endometrial Carcinoma, Obese | Phase 2 / Phase 3 | Terminated | Xiaojun Chen | 8 | 2022-05-01 | 2026-06-04 |
| Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer Megestrol Acetate 160 MG Oral Tablet, Medroxyprogesterone Acetate 500 MG, Triprorelin Acetate - Endometrial Neoplasm Malignant Stage I | Phase 2 | Recruiting | Fudan University | 104 | 2022-03-11 | 2026-06-04 |
Showing 20 of 80. Sign in to see all of them.
Endometrial Neoplasms (20) · Anorexia (15) · Endometrial Hyperplasia (15) · Cachexia (14) · Breast Neoplasms (8) · Neoplasms (8) · HIV Infections (7) · Weight Loss (6) · Acquired Immunodeficiency Syndrome (4) · Body Weight (4) · Infertility (4) · Obesity (4) · Body Weight Changes (3) · HIV Wasting Syndrome (3) · Overweight (3)
Fudan University (7) · Wake Forest University Health Sciences (4) · Xiaojun Chen (4) · Bristol-Myers Squibb (3) · Par Pharmaceutical, Inc. (3) · Alliance for Clinical Trials in Oncology (2) · Asan Medical Center (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · Gynecologic Oncology Group (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Northwestern University (2) · Rottapharm Spain (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1)
United States (32) · China (20) · Canada (6) · Spain (4) · United Kingdom (4) · Brazil (3) · Singapore (3) · South Korea (3) · Taiwan (3) · Bangladesh (2) · Puerto Rico (2) · Thailand (2) · Argentina (1) · Belgium (1) · Burma (1)
Aminah Jatoi, MD (2) · Edward G. Shaw, MD (2) · Lynn D Kramer, MD (2) · Xiaojun Chen, PhD (2) · Alfredo Berruti (1) · Almudena Garnica, MD (1) · Bart Frizzell, MD (1) · Benoit Deschamps, MD (1) · Bojana Djordjevic, MD (1) · Carolyn Y Muller (1) · Chaoting Zhao, MD (1) · Charles L. Wiseman, MD, FACP (1) · Curtis Lockshin, PhD (1)
PMID 15197210, PMID 18375894, PMID 18989154, PMID 19774117, PMID 21524765, PMID 21863030, PMID 22551107, PMID 27191767, PMID 27626976, PMID 30367443, PMID 32861807, PMID 32909630, PMID 33981288, PMID 36562136, PMID 36999619, PMID 37182434, PMID 39215793, PMID 41492093
U10CA180868 (2), 2009 (1), 2016 (1), P01CA278735 (1), P30CA012197 (1), P30CA014089 (1), P30CA033572 (1), P30CA060553 (1), P30CA118100 (1), U10CA027469 (1), U10CA037429 (1), U10CA081851 (1), U10CA081920 (1), U10CA101165 (1), UG1CA189823 (1)